RxDoctor Payments Data

Louis Mazzella, MD

General Practice · Saint Petersburg, FLNPI 1508029323

Payments from drug & device makers

$5,270in general payments, 2019–2025

Across 161 payments — averaging $32.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$5K
  • Cipher Pharmaceuticals US LLC$194
  • Solventum Corporation$133
  • Kerecis Limited$114
  • Organogenesis Inc.$83
  • Avanir Pharmaceuticals, Inc.$13

What the payments were for

  • Travel & lodging$1,37326%
  • Food & beverage$3,89774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew155$4,733
Cipher Pharmaceuticals US LLC1$194
Solventum Corporation1$133
Kerecis Limited1$114
Organogenesis Inc.2$83
Avanir Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,270 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$4,365,233
Medicare patients
601
Services billed
8,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.330$699,731
JulucaDolutegravir/Rilpivirine11$44,971
ErtapenemErtapenem Sodium59$31,278
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam24$4,561
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip117$3,362
MyrbetriqMirabegron14$3,246
NyamycNystatin45$2,143
Vancomycin Hcl28$1,813
Doxycycline Hyclate29$911
Ketoconazole17$808
Fluconazole24$736
Sodium Chloride0.9 % Sodium Chloride12$692
Nystatin11$499
Triamcinolone Acetonide24$277
Prednisone11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$4,733$699,731330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →